Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Sana Biotechnology, retaining the price target of $7.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar has given his Buy rating due to a combination of factors including continued clinical validation of Sana’s hypoimmune (HIP) technology and progress toward key 2026 milestones. She highlights that the 14‑month follow‑up in the UP421 study showed a rebound in C‑peptide levels at a microdose, supporting durable islet cell function without immunosuppression and lowering perceived biological risk for the SC451 program.
She also emphasizes that SC451 remains on track for an IND filing and Phase 1 initiation in 2026, with higher iPSC‑derived cell doses aimed at achieving full glycemic control and insulin independence in Type 1 Diabetes. In addition, the strategic collaboration and equity investment from the Mayo Clinic provide external validation, operational support for trial execution, and incremental capital, reinforcing her unchanged $7 price target and underpinning a favorable risk‑reward profile for SANA shares.